Rapid Readouts

Rapid Readouts: Larotrectinib in Advanced TRK Fusion Thyroid Cancer

ByMaria E. Cabanillas, MD, MD Anderson Cancer Center

January 19th 2021

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

ByMatthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute

January 18th 2021

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

ByPeter Voorhees, MD

January 18th 2021

Rapid Readouts: Phase 2 Study of Navitoclax in High-Risk Myelofibrosis

ByCatriona Jamieson, MD, PhD, University of California San Diego

January 15th 2021

Rapid Readouts: Results from the Phase 3 ANDROMEDA Study

ByRaymond L. Comenzo, MD, Tufts Medical Center

January 14th 2021

Rapid Readouts: Five-Year Analysis of MURANO Study

ByMatthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute

December 23rd 2020

Rapid Readouts: Updated Results From KX-ORAX-001 Study

ByDawn L. Hershman, MD, Herbert Irving Comprehensive Cancer Center at Columbia University

December 23rd 2020

Rapid Readouts: Phase 1b/2 CARTITUDE-1 Study

ByDeepu Madduri, MD, Mount Sinai Hospital

December 23rd 2020

Rapid Readouts: Updated Results From DESTINY-Breast01

BySara A. Hurvitz, MD, University of California, Los Angeles

December 23rd 2020

Rapid Readouts: Momelotinib's Spleen, Symptom, and Anemia Efficacy

BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center

December 10th 2020

Rapid Readouts: Long-Term Results from SIMPLIFY-1 and SIMPLIFY-2

BySrdan Verstovsek, MD, PhD, MD Anderson Cancer Center

December 10th 2020

Rapid Readouts: Phase 3 VIALE-A Study

ByVinod Pullarkat, MD, City of Hope Medical Center

December 3rd 2020

Rapid Readouts: Phase 1/2 KRYSTAL-1 Trial

ByPasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute

November 18th 2020

Rapids Readouts: Phase 3 CheckMate 238 Trial

ByJeffrey Weber, MD, PhD, NYU Langone Health, Perlmutter Cancer Center

October 30th 2020

Rapid Readouts: TROPHY-U-01 Cohort 1 Final Results

ByCora Sternberg, MD, FACP, Weill Cornell Medicine

October 14th 2020

Rapid Readouts: Phase 3 HERO Trial

ByNeal D. Shore, MD, FACS, Carolina Urologic Research Center

October 8th 2020

Rapid Readouts: Phase 3 CheckMate 9ER Trial

ByRana R. McKay, MD, University of California, San Diego

October 7th 2020

Rapid Readouts: Phase 3 ASCENT Study

ByAditya Bardia, MD, Massachusetts General Hospital Cancer Center

October 5th 2020

Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial

ByBradley J. Monk, MD, FACS, FACOG, Arizona Oncology

August 24th 2020

Rapid Readouts: Phase 1/2 Study Results of Liposomal Irinotecan and FOLFOX

ByZev A. Wainberg, MD

July 17th 2020

Rapid Readouts: Initial Results of the Phase III BOSTON Study

ByCristina Gasparetto, MD, Duke Cancer Institute

June 29th 2020

Rapid Readouts: The SOLO2 / ENGOT Ov-21 Trial

ByKathleen N. Moore, MD, Stephenson Cancer Center

June 25th 2020

Rapid Readouts: Three-Year Update From CheckMate 227, Part 1

BySuresh S. Ramalingam, MD, FASCO, Winship Cancer Institute of Emory University

June 23rd 2020

Rapid Readouts: Final Analysis of KEYNOTE-189

ByEdward Garon, MD, Jonsson Comprehensive Cancer Center at UCLA

June 23rd 2020

Rapid Readouts: Update of CARTITUDE-1

BySaad Z. Usmani, MD, FACP, Levine Cancer Institute

June 23rd 2020

Rapid Readouts: The TIVO-3 Study of Tivozanib in Metastatic Renal Cell Carcinoma

BySumanta K. Pal, MD, City of Hope Comprehensive Cancer Center

June 19th 2020

Rapid Readouts: CheckMate 9LA

ByMartin Reck, MD, PhD, Lung Clinic Grosshansdorf

June 16th 2020

Rapid Readouts: JAVELIN Bladder 100 Phase III Interim Analysis

ByPetros Grivas MD, PhD

June 16th 2020

Rapid Readouts

Rapid Readouts: Larotrectinib in Advanced TRK Fusion Thyroid Cancer

Rapid Readouts: Efficacy of Novel Targeted Therapies Post-MURANO Study

Rapid Readouts: The Phase 1/2 ANCHOR Trial for Melphalan Flufenamide in Relapsed/Refractory Multiple Myeloma

Rapid Readouts: Phase 2 Study of Navitoclax in High-Risk Myelofibrosis

Rapid Readouts: Results from the Phase 3 ANDROMEDA Study

Rapid Readouts: Five-Year Analysis of MURANO Study

Rapid Readouts: Updated Results From KX-ORAX-001 Study

Rapid Readouts: Phase 1b/2 CARTITUDE-1 Study

Rapid Readouts: Updated Results From DESTINY-Breast01

Rapid Readouts: Momelotinib's Spleen, Symptom, and Anemia Efficacy

Rapid Readouts: Long-Term Results from SIMPLIFY-1 and SIMPLIFY-2

Rapid Readouts: Phase 3 VIALE-A Study

Rapid Readouts: Phase 1/2 KRYSTAL-1 Trial

Rapids Readouts: Phase 3 CheckMate 238 Trial

Rapid Readouts: TROPHY-U-01 Cohort 1 Final Results

Rapid Readouts: Phase 3 HERO Trial

Rapid Readouts: Phase 3 CheckMate 9ER Trial

Rapid Readouts: Phase 3 ASCENT Study

Rapid Readouts: Phase III PAOLA-1/ENGOT-ov25 Trial

Rapid Readouts: Phase 1/2 Study Results of Liposomal Irinotecan and FOLFOX

Rapid Readouts: Initial Results of the Phase III BOSTON Study

Rapid Readouts: The SOLO2 / ENGOT Ov-21 Trial

Rapid Readouts: Three-Year Update From CheckMate 227, Part 1

Rapid Readouts: Final Analysis of KEYNOTE-189

Rapid Readouts: Update of CARTITUDE-1

Rapid Readouts: The TIVO-3 Study of Tivozanib in Metastatic Renal Cell Carcinoma

Rapid Readouts: CheckMate 9LA

Rapid Readouts: JAVELIN Bladder 100 Phase III Interim Analysis

Trending on OncLive

FDA Approves Pirtobrutinib for Previously Untreated CLL/SLL

The OncFive: Top Oncology Articles for the Week of 9/27/2026

AUA Releases Guideline Amendment for NMIBC

FLORA-2 Updates at World Lung: Biomarker Analysis, Safety Follow-Up, and ctDNA Monitoring

Daraxonrasib Approval Signals a New Era for RAS-Targeted Therapy in Pancreatic Cancer